DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia
NCT ID: NCT02532686
Last Updated: 2018-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2014-10-31
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DAAOI-1 Treatment for Treatment-resistant Schizophrenia
NCT01390376
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
NCT00960219
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
NCT04959201
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
NCT06021197
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
NCT06574360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this project is to examine the effectiveness and safety of DAAOI-2 add-on treatment for treatment resistant schizophrenia patients in a randomized, double-blind, placebo - controlled trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DAAOI-2
DAAOI-2: 500-2000mg/d
DAAOI-2
500-2000mg/d, oral, for 6 weeks
placebo
placebo
oral, for 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DAAOI-2
500-2000mg/d, oral, for 6 weeks
placebo
oral, for 6 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment resistant: No satisfactory response to at least two kinds of antipsychotics
* Remain symptomatic but without clinically significant fluctuation and the antipsychotic doses are unchanged for at least 3 months
* Have a minimum baseline total score of 70 on the Positive and Negative Syndrome Scale (PANSS)
* Agree to participate in the study and provide informed consent
Exclusion Criteria
* Meet DSM-IV criteria of mental retardation
* Serious medical or neurological illness
* Pregnancy or lactation
* Inability to follow protocol
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Science and Technology, Taiwan
OTHER_GOV
China Medical University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hsien-Yuan Lane
Department of Psychiatry
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry, China Medical University Hospital
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NSC-101-2314-B-039-030-MY3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.